Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Utah Clinical Trials
mi
from
Salt Lake City, UT
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Utah Clinical Trials
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
University of Wisconsin
mi
from
Madison, WI
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study
Status: Enrolling
Updated:  8/9/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study
Status: Enrolling
Updated: 8/9/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma
A Pilot Trial to Assess Mobilization of Hematopoietic Progenitor Cells With a Combination of Bortezomib and G-CSF in Patients Undergoing Autologous Transplant for Myeloma and Lymphoma
Status: Enrolling
Updated:  8/14/2012
University of Kansas Medical Center
mi
from
Kansas City, KA
A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma
A Pilot Trial to Assess Mobilization of Hematopoietic Progenitor Cells With a Combination of Bortezomib and G-CSF in Patients Undergoing Autologous Transplant for Myeloma and Lymphoma
Status: Enrolling
Updated: 8/14/2012
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma
A Pilot Trial to Assess Mobilization of Hematopoietic Progenitor Cells With a Combination of Bortezomib and G-CSF in Patients Undergoing Autologous Transplant for Myeloma and Lymphoma
Status: Enrolling
Updated:  8/14/2012
University of Kansas Medical Center, Westwood Campus
mi
from
Kansas City, KA
A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma
A Pilot Trial to Assess Mobilization of Hematopoietic Progenitor Cells With a Combination of Bortezomib and G-CSF in Patients Undergoing Autologous Transplant for Myeloma and Lymphoma
Status: Enrolling
Updated: 8/14/2012
University of Kansas Medical Center, Westwood Campus
mi
from
Kansas City, KA
Click here to add this to my saved trials
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies
Status: Enrolling
Updated:  9/8/2012
University of Alabama in Birmingham BMT/CT Program Outpatient Clinic
mi
from
Birmingham, AL
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies
Status: Enrolling
Updated: 9/8/2012
University of Alabama in Birmingham BMT/CT Program Outpatient Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Evaluation of Plerixafor (Mozobil ™, AMD3100) in Combination With Chemotherapy and G-CSF for CD34+ Cell Mobilization
Status: Enrolling
Updated:  9/18/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Evaluation of Plerixafor (Mozobil ™, AMD3100) in Combination With Chemotherapy and G-CSF for CD34+ Cell Mobilization
Status: Enrolling
Updated: 9/18/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/24/2012
Alabama at Birmingham Comprehensive Cancer Center
mi
from
Birmingham, AL
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/24/2012
Alabama at Birmingham Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/24/2012
Georgetown University Hospital Lombardi Cancer Center
mi
from
Washington,
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/24/2012
Georgetown University Hospital Lombardi Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/24/2012
M. D. Anderson Cancer Center
mi
from
Orlando, FL
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/24/2012
M. D. Anderson Cancer Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/24/2012
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/24/2012
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/24/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/24/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Aurora, CO
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Boston, MA
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Newark, NJ
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
An Exploratory, Open Label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Status: Enrolling
Updated:  10/22/2012
Center for LAM Research and Clinical Care
mi
from
Boston, MA
A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
An Exploratory, Open Label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Status: Enrolling
Updated: 10/22/2012
Center for LAM Research and Clinical Care
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
An Exploratory, Open Label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Status: Enrolling
Updated:  10/22/2012
University of Cincinnati - Department of Internal Medicine Pulmonary, Critical Care & Sleep Medicine
mi
from
Cincinnati, OH
A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
An Exploratory, Open Label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Status: Enrolling
Updated: 10/22/2012
University of Cincinnati - Department of Internal Medicine Pulmonary, Critical Care & Sleep Medicine
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
An Exploratory, Open Label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Status: Enrolling
Updated:  10/22/2012
Novartis Investigative Site
mi
from
Lyon,
A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
An Exploratory, Open Label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Status: Enrolling
Updated: 10/22/2012
Novartis Investigative Site
mi
from
Lyon,
Click here to add this to my saved trials
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated:  11/5/2012
The University of Arizona Cancer Center
mi
from
Tucson, AZ
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated: 11/5/2012
The University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated:  11/5/2012
City of Hope National Medical Center
mi
from
Duarte, CA
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated: 11/5/2012
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated:  11/5/2012
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated: 11/5/2012
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated:  11/5/2012
Rocky Mountain Blood and Marrow Transplant Program
mi
from
Denver, CO
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated: 11/5/2012
Rocky Mountain Blood and Marrow Transplant Program
mi
from
Denver, CO
Click here to add this to my saved trials
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated:  11/5/2012
Loyola University Medical Center
mi
from
Proviso, IL
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated: 11/5/2012
Loyola University Medical Center
mi
from
Proviso, IL
Click here to add this to my saved trials
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated:  11/5/2012
Indiana Blood and Marrow Transplantation
mi
from
Beech Grove, IN
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated: 11/5/2012
Indiana Blood and Marrow Transplantation
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated:  11/5/2012
University of Mississippi Medical Center
mi
from
Jackson, MS
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated: 11/5/2012
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated:  11/5/2012
Univ of Rochester Medical Center
mi
from
Rochester, NY
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated: 11/5/2012
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated:  11/5/2012
Medical University of South Carolina
mi
from
Charleston, SC
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg
Status: Enrolling
Updated: 11/5/2012
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL
A Phase II, Single Arm Study Examining the Combination of Lenalidomide and Azacitidine (RA-CLL) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated:  11/7/2012
Hackensack University Medical Center
mi
from
Hackensack, NJ
Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL
A Phase II, Single Arm Study Examining the Combination of Lenalidomide and Azacitidine (RA-CLL) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated: 11/7/2012
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
A Phase I Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  11/12/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
A Phase I Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 11/12/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CML, ALL, MDS, and B Cell Malignancies
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CmML, ALL, MDS, and B Cell Malignancies
Status: Enrolling
Updated:  11/15/2012
Duke Comprehensive Cancer Center
mi
from
Durham, NC
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CML, ALL, MDS, and B Cell Malignancies
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CmML, ALL, MDS, and B Cell Malignancies
Status: Enrolling
Updated: 11/15/2012
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
A Phase II Open-label Study of Single Agent Ofatumumab in Patients With Relapsed and/or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
Status: Enrolling
Updated:  12/7/2012
University of Illinois at Chicago
mi
from
Chicago, IL
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
A Phase II Open-label Study of Single Agent Ofatumumab in Patients With Relapsed and/or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
Status: Enrolling
Updated: 12/7/2012
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
A Phase II Open-label Study of Single Agent Ofatumumab in Patients With Relapsed and/or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
Status: Enrolling
Updated:  12/7/2012
Oncology Specialists, S.C
mi
from
Skokie, IL
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
A Phase II Open-label Study of Single Agent Ofatumumab in Patients With Relapsed and/or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
Status: Enrolling
Updated: 12/7/2012
Oncology Specialists, S.C
mi
from
Skokie, IL
Click here to add this to my saved trials
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
A Phase II Open-label Study of Single Agent Ofatumumab in Patients With Relapsed and/or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
Status: Enrolling
Updated:  12/7/2012
Oncology Specialists, SC
mi
from
Park Ridge, IL
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
A Phase II Open-label Study of Single Agent Ofatumumab in Patients With Relapsed and/or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
Status: Enrolling
Updated: 12/7/2012
Oncology Specialists, SC
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of Intermittent, Once Weekly, and Continuous Daily Oral OSI-027 Dosing in Patients With Advanced Solid Tumors or Lymphoma
Status: Enrolling
Updated:  12/19/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of Intermittent, Once Weekly, and Continuous Daily Oral OSI-027 Dosing in Patients With Advanced Solid Tumors or Lymphoma
Status: Enrolling
Updated: 12/19/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
Status: Enrolling
Updated:  12/19/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
Status: Enrolling
Updated: 12/19/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated:  1/7/2013
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated: 1/7/2013
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated:  1/7/2013
UCLA Clinical AIDS Research and Education (CARE) Center
mi
from
Los Angeles, CA
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated: 1/7/2013
UCLA Clinical AIDS Research and Education (CARE) Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated:  1/7/2013
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated: 1/7/2013
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated:  1/7/2013
University of California at Davis Center for Aids Research and Education Services
mi
from
Sacramento, CA
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated: 1/7/2013
University of California at Davis Center for Aids Research and Education Services
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated:  1/7/2013
Veterans Affairs Medical Center - San Diego
mi
from
San Diego, CA
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated: 1/7/2013
Veterans Affairs Medical Center - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated:  1/7/2013
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated: 1/7/2013
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated:  1/7/2013
University of Miami
mi
from
Miami, FL
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated: 1/7/2013
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated:  1/7/2013
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated: 1/7/2013
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated:  1/7/2013
Boston University Cancer Research Center
mi
from
Boston, MA
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated: 1/7/2013
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated:  1/7/2013
Mallinckrodt Institute of Radiology at Washington University Medical Center
mi
from
St. Louis, MO
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated: 1/7/2013
Mallinckrodt Institute of Radiology at Washington University Medical Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated:  1/7/2013
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated: 1/7/2013
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated:  1/7/2013
Montefiore Medical Center
mi
from
Bronx, NY
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas
Status: Enrolling
Updated: 1/7/2013
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials